Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

Positive clinical trial results for nutritional shake bolsters $5m cap raise

  • In News
  • September 2, 2021
  • Samantha Freidin
Positive clinical trial results for nutritional shake bolsters $5m cap raise

Days after raising $5 million via a capital raise to accelerate their global strategy, Nutritional Growth Solutions (ASX: NGS) has released clinical trial data showing positive results for their product Healthy Heights Grow Daily Boys 10+. 

Just one of their growing range of products, Nutritional Growth Solutions creates clinically tested nutritional supplements for children, a surprisingly overlooked corner of the supplementation market. 

Backed by 20 years of research into paediatric nutrition at Israel’s largest paediatric hospital, the Company has been rapidly expanding into global markets, most recently launching their proprietary Healthy Height shake range in Chemist Warehouse and on T-Mall Global in China. 

The most recent 12 month, randomised, double- blinded and placebo controlled study evaluated the effects of the formula on 160 healthy but lean and short, pre adolescent males between the ages of 10-14.5 years old. The study was carried out in two phases- the first, a double-blinded administration of nutritional formula or placebo, followed by an open-label extension of the study with the nutritional formula given to all participants. 

The results showed a notable increase in the weight, BMI and muscle mass of participants who consumed Healthy Heights Grow Daily Boys 10+ over six-months, compared to those consuming the placebo. 

Interestingly, children over 11.4 years who participated in the study maintained their height increase rate, however children taking the placebo displayed a decrease in height increase rate.  

The dose of nutritional formula directly correlated with changes in growth. In short, it looks like this product really works. 

Lead researcher of the study, Dr. Michal Yackobovitch-Gavan commented: “ Intervention with a multi-nutrient, protein-rich formula was effective at increasing weight, fat-free mass, muscle mass, and BMI in short and lean pre-pubertal male adolescents. It also prevented the expected decline in height increase rate in older participants. All the participants were with no pubertal signs at the study entry. Hence, older participants were with delayed puberty as compared to their peers, and expected to grow slower as compared to children in the same age who already have begun their pubertal growth spurt. 

“This is a key trial that evaluated the importance of nutrition for pre-adolescents and is certain to inspire more research.” 

NGS CEO and Managing Director, Liron Fendell was encouraged by the findings, saying: “ As we launch Grow Daily Boys 10+ to market, it is great to have the clinical trial findings to verify the positive effect on growth for teen and pre-teen boys. 

“As we continue to build relationships with pharmacies and health food stores around the world, we also ensure they are equipped to educate buyers about what the trial findings mean and the best way to use the product for their child.  

“The make-up of nutrients required for optimal growth changes throughout a child;s growing years and this is why we created a formulation specifically for boys aged 10 and over. Our new Grow Daily Boys 10+ range contains all the essential micro nutrients, such as calcium and iron with high protein needed for optimal growth in pre-teens. 

“With both the Grow Daily Boys 10+ and Healthy Height product for children aged 3-9 officially proven to increase growth development in young people, we look forward to testing our formulas in different ways, such as our trials on children treating ADHD with stimulant medication, as well as on additional innovative products we look to bring to market.” 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • growth supplements
  • michael yackobovitch-gavan
  • ngs
  • nutritional growth solutions
  • paediatric nutrition
  • tmall
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.